Benitec Biopharma initiated work on two new oncology pipeline programs after executing a research collaboration agreement with Nant Capital LLC. Under the terms of the agreement, Benitec has taken control of the clinical development of BB-401, a recombinant DNA construct that produces an antisense RNA with specificity against Epidermal Growth Factor Receptor. It has assembled a team of experts to articulate the plans for the rapid progression of BB-401 into the next stages of development, which includes plans to meet with the Food and Drug Administration and other regulatory agencies and targets starting a midstage human clinical study early in 2018.